Suppliers / Curium US

Curium US

United States Updated 9 July 2026

Curium US is an API manufacturer based in United States. It holds 9 active US drug master files across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 18 April 2025 as VAI.

9
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
18
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 18 April 2025 VAI US FDA
  • 18 August 2023 VAI US FDA
  • 14 June 2019 NAI US FDA
  • 13 November 2015 VAI US FDA
  • 18 June 2014 NAI US FDA
  • 27 March 2013 NAI US FDA
  • 6 August 2012 VAI US FDA
  • 25 May 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Noblesville, United States 3011400787
Maryland Heights, United States 1946929

What they file, and where

Molecule Regulators Docs
Copper Oxodotreotide Cu-64 US FDA 1
Cupric Chloride US FDA 1
Gallium Chloride Ga-67 US FDA 1
Indium US FDA 1
Indium In-111 Chloride US FDA 1
Iodide I-123 US FDA 1
Leucine US FDA 1
Molybdate US FDA 1
Pentetic Acid US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 18 2

Comparing suppliers?

Choose your molecules and target markets. Curium US comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 18 April 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates